Wall Street analysts expect Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings per share (EPS) of $0.17 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Diplomat Pharmacy’s earnings. The lowest EPS estimate is $0.15 and the highest is $0.18. Diplomat Pharmacy reported earnings of $0.08 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 112.5%. The firm is expected to report its next earnings results on Tuesday, February 27th.

On average, analysts expect that Diplomat Pharmacy will report full year earnings of $0.84 per share for the current financial year, with EPS estimates ranging from $0.77 to $0.86. For the next fiscal year, analysts forecast that the company will post earnings of $0.97 per share, with EPS estimates ranging from $0.77 to $1.36. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the company posted $0.21 EPS. The company’s quarterly revenue was down 4.8% compared to the same quarter last year.

Several research firms have weighed in on DPLO. Needham & Company LLC lifted their price objective on shares of Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, January 8th. Leerink Swann upgraded shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a research report on Monday, December 11th. Deutsche Bank initiated coverage on shares of Diplomat Pharmacy in a research report on Monday, December 4th. They set a “buy” rating and a $22.00 price objective on the stock. Robert W. Baird cut shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $24.00 to $18.00 in a report on Thursday, November 16th. Finally, BidaskClub cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $20.94.

In other Diplomat Pharmacy news, President Joel Saban acquired 10,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was acquired at an average price of $15.24 per share, with a total value of $152,400.00. Following the purchase, the president now owns 12,000 shares in the company, valued at $182,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Atul Kavthekar acquired 2,000 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, November 20th. The stock was acquired at an average cost of $15.00 per share, with a total value of $30,000.00. Following the purchase, the chief financial officer now owns 2,000 shares in the company, valued at approximately $30,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 15,000 shares of company stock worth $228,780. 30.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its stake in shares of Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the last quarter. First Allied Advisory Services Inc. acquired a new stake in shares of Diplomat Pharmacy in the 2nd quarter valued at $183,000. SG Americas Securities LLC acquired a new stake in shares of Diplomat Pharmacy in the 3rd quarter valued at $191,000. BNP Paribas Arbitrage SA lifted its stake in shares of Diplomat Pharmacy by 57.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,992 shares of the company’s stock valued at $207,000 after purchasing an additional 5,116 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Diplomat Pharmacy by 478.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 14,600 shares of the company’s stock valued at $216,000 after purchasing an additional 12,076 shares during the last quarter. 72.21% of the stock is owned by institutional investors and hedge funds.

Diplomat Pharmacy (NYSE:DPLO) opened at $25.93 on Tuesday. Diplomat Pharmacy has a 52-week low of $12.76 and a 52-week high of $26.17. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34. The firm has a market cap of $1,790.00, a P/E ratio of 216.08, a price-to-earnings-growth ratio of 4.07 and a beta of 0.62.

COPYRIGHT VIOLATION WARNING: “Diplomat Pharmacy Inc (DPLO) Expected to Announce Earnings of $0.17 Per Share” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2018/01/16/diplomat-pharmacy-inc-dplo-expected-to-announce-earnings-of-0-17-per-share.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Stock Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related stocks with our FREE daily email newsletter.